Interleukin-enhanced CAR-engineered immune cells in tumor immunotherapy: current insights and future perspectives
{{output}}
Despite the remarkable clinical success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies, the therapeutic efficacy of conventional second-generation CAR-T cells in treating solid tumors remains suboptimal, primarily due to three ma... ...
